ImmunoCellular Investor Presentation

January 2010 Manish Singh, PhD President and CEO OTC BB: IMUC.OB www.imuc.com

SEC Disclaimer Statement ,[object Object],January 2010

Mission ,[object Object],January 2010

Cancer Stem Cells: Good Guys Turned Bad ,[object Object],[object Object],January 2010 Targeting CSCs may significantly delay or prevent disease recurrences. Normal Stem Cell mutations Cancer Stem Cell Mature Tissue Bulk Tumor Progenitor cells

Technology Overview: Utilizing Both Arms of Immune System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

ICT-107: Dendritic Cell-Based Vaccine Targeting Cancer Stem Cells and Tumor Associated Antigens January 2010 Antigens Tumor Expression CSC Expression gp100 Melanoma, brain cancer Trp-2 Melanoma and brain cancer High Her-2/neu Breast, ovarian cancer Medium MAGE-1 Melanoma, brain cancer AIM Breast, ovarian, colon, brain High IL-13aR2 Brain cancer

January 2010 Significant Improvement in Progression-Free Survival (Compared to Historical Controls Using Standard of Care) Radiation + Temozolomide* Radiation + Temozolomide +ICT-107 ,[object Object],[object Object]

Summary of Clinical Data: Progression-Free and Overall Survival January 2010 SOC = Standard of care (surgery + radiation + Temozolomide) Newly Diagnosed (16) SOC + ICT-107 Historical Control (SOC) Median PFS (months) 19.0 6.9 Median OS (months) > 21 14.2 % Survival at 12 months 94% 60% % Survival at 21 months 80% 30% Recurrent (3) Median OS (months) 30.5 7.0 (9.2 with Avastin+SOC)

ICT-121: Cancer Stem Cell Vaccine ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010 Potential Blockbuster Product

Summary of Antibody Programs January 2010 ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Value Creation Catalysts in Next 12 Months ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Management Team ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Key Opinion Leaders ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Financial Position and Capitalization ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

Summary ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],January 2010

ImmunoCellular Investor Presentation

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Was ist angesagt?

Was ist angesagt? (19)

Ähnlich wie ImmunoCellular Investor Presentation

Ähnlich wie ImmunoCellular Investor Presentation (20)

Mehr von Chelli Miller

Mehr von Chelli Miller (9)

Kürzlich hochgeladen

Kürzlich hochgeladen (20)

ImmunoCellular Investor Presentation